Kythera Biopharmaceuticals, Inc. (KYTH)
-NasdaqGS | Prev Close: | 21.00 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 28.67 |
|---|
| Beta: | -4.645 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 14.07 - 31.93 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 61,405 |
|---|
| Market Cap: | 386.06M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.86 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- KYTHERA BIOPHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 21)
- KYTHERA Biopharmaceuticals Announces First Quarter 2013 Operating ResultsGlobeNewswire(Mon, May 13)
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementEDGAR Online(Mon, May 13)
- Q1 2013 Kythera Biopharmaceuticals Earnings Release - Time Not SuppliedCCBN(Mon, May 13)
- KYTHERA Biopharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare ConferenceGlobeNewswire(Tue, May 7)
- KYTHERA Biopharmaceuticals to Release First Quarter 2013 Operating ResultsGlobeNewswire(Thu, May 2)
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other EventsEDGAR Online(Thu, Apr 25)
- KYTHERA Biopharmaceuticals, Inc. Presents Positive Magnetic Resonance Imaging (MRI) Results from Phase IIb Study of ATX-101 in the Reduction of Submental Fat or “Double Chin”Business Wire(Sat, Apr 13)
- Data Presented on Bayer's ATX-101Zacks(Mon, Apr 8)
- KYTHERA Biopharmaceuticals, Inc. Announces Positive Interim Results from Open-Label Phase IIIb Study of ATX-101 at the 11th Anti-Aging Medicine World Congress (AMWC)Business Wire(Sat, Apr 6)
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online(Fri, Apr 5)
- Is Kythera's Double Chin Drug A Winner?at Seeking Alpha(Tue, Apr 2)
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements anEDGAR Online(Tue, Apr 2)
- KYTHERA BIOPHARMACEUTICALS INC Files SEC form 10-K, Annual ReportEDGAR Online(Tue, Mar 26)
- KYTHERA Biopharmaceuticals Announces 2012 Operating ResultsBusiness Wire(Thu, Mar 21)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 21.73 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -2.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.70 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.75 |
|---|
Business Summary
KYTHERA Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of prescription products for the aesthetic medicine market.
View More 
0.34%